How big is Harrow, Inc.?

As of Jun 18, Harrow, Inc. has a market capitalization of 1,116.03 million, with net sales of 212.86 million and a net profit of -21.69 million over the latest four quarters.

Market Cap: As of Jun 18, Harrow, Inc. has a market capitalization of 1,116.03 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Harrow, Inc. reported net sales of 212.86 million and a net profit of -21.69 million.<BR><BR>Balance Sheet Snapshot: As of Dec'24, the company reported shareholder's funds of 69.65 million and total assets of 388.97 million.

What does Harrow, Inc. do?

Harrow, Inc. is a pharmaceutical company specializing in ophthalmology pharmaceutical compounding, with recent net sales of $48 million and a net profit of -$18 million. The company has a market cap of approximately $1.12 billion.

Overview:<BR>Harrow, Inc. operates in the Pharmaceuticals & Biotechnology industry, focusing on a diversified portfolio of healthcare businesses, including ophthalmology pharmaceutical compounding.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 48 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -18 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 1,116.03 Million (Micro Cap) <BR><BR>Key Metrics:<BR>Debt Equity: 2.74 <BR>Return on Equity: -37.99% <BR>Price to Book: 19.77 <BR><BR>Contact Details:<BR>Address: 102 WOODMONT BLVD, SUITE 610, NASHVILLE TN: 37215 <BR>Tel: 1 615 7334731 <BR>Website: http://www.imprimisrx.com/

Should I buy, sell or hold Harrow, Inc.?

Who are in the management team of Harrow, Inc.?

As of March 2022, the management team of Harrow, Inc. includes Dr. Robert Kammer (Independent Chairman), Mr. Mark Baum (CEO and Director), Dr. Richard Lindstrom (Director), Ms. Teresa Sparks (Independent Director), and Prof. R. Lawrence Van Horn (Independent Director).

As of March 2022, the management team of Harrow, Inc. includes the following individuals:<BR><BR>- Dr. Robert Kammer, who serves as the Independent Chairman of the Board.<BR>- Mr. Mark Baum, who is the Chief Executive Officer and a Director.<BR>- Dr. Richard Lindstrom, who is a Director.<BR>- Ms. Teresa Sparks, who is an Independent Director.<BR>- Prof. R. Lawrence Van Horn, who is also an Independent Director.

Is Harrow, Inc. overvalued or undervalued?

Harrow, Inc. has shifted from a fair to a risky valuation grade due to being overvalued with significant losses, a troubling ROE of -37.99%, and high valuation ratios compared to peers, despite a strong stock performance over the past three years.

As of 9 November 2021, the valuation grade for Harrow, Inc. moved from fair to risky, indicating a shift towards a more negative outlook. The company appears to be overvalued, particularly given its significant losses reflected in the P/E ratio of NA and a troubling ROE of -37.99%. Key ratios such as the Price to Book Value at 19.24 and the EV to EBITDA at 58.98 further underscore the valuation concerns.<BR><BR>In comparison to its peers, Harrow, Inc. has a notably high EV to EBIT of 260.04, while Travere Therapeutics, Inc. and Tarsus Pharmaceuticals, Inc. exhibit lower EV to EBITDA ratios of -16.22 and -21.71, respectively. Despite recent strong stock performance, with a 3-year return of 404.78% compared to the S&P 500's 70.41%, the underlying financial metrics suggest that Harrow, Inc. is not positioned favorably in the current market.

Is Harrow, Inc. technically bullish or bearish?

As of October 10, 2025, Harrow, Inc. shows a mildly bullish trend with positive weekly indicators, a year-to-date return of 15.56% outperforming the S&P 500, but a yearly return of -23.55% underperforming the index.

As of 10 October 2025, the technical trend for Harrow, Inc. has changed from bullish to mildly bullish. The weekly MACD and KST indicators are bullish, while the monthly KST is mildly bearish. The Bollinger Bands and moving averages indicate a mildly bullish stance on both weekly and daily time frames. The Dow Theory shows a mildly bullish trend on the weekly chart, but no trend on the monthly chart. <BR><BR>In terms of performance, Harrow, Inc. has a year-to-date return of 15.56%, outperforming the S&P 500's 11.41%, but it has underperformed over the past year with a return of -23.55% compared to the S&P 500's 13.36%. Overall, the current technical stance is mildly bullish, with key indicators supporting this view.